Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more
Aarti Drugs Limited (AARTIDRUGS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.104x
Based on the latest financial reports, Aarti Drugs Limited (AARTIDRUGS) has a cash flow conversion efficiency ratio of 0.104x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹1.52 Billion) by net assets (₹14.69 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aarti Drugs Limited - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Aarti Drugs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aarti Drugs Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aarti Drugs Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
QST International
TWO:8349
|
0.030x |
|
Shandong Huifa Foodstuff Co
SHG:603536
|
-0.075x |
|
Israir Group Ltd
TA:ISRG
|
0.016x |
|
Global Tax Free Co. Ltd
KQ:204620
|
0.123x |
|
Fentura Financial Inc
OTCQX:FETM
|
0.065x |
|
Focus Lightings Tech Co Ltd
SHE:300708
|
0.055x |
|
Risuntek Inc
SHE:002981
|
0.022x |
|
Heliostar Metals Ltd
OTCQX:HSTXF
|
0.076x |
Annual Cash Flow Conversion Efficiency for Aarti Drugs Limited (2007–2025)
The table below shows the annual cash flow conversion efficiency of Aarti Drugs Limited from 2007 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹13.69 Billion | ₹2.45 Billion | 0.179x | -36.21% |
| 2024-03-31 | ₹12.82 Billion | ₹3.59 Billion | 0.280x | +148.83% |
| 2023-03-31 | ₹11.93 Billion | ₹1.34 Billion | 0.113x | +67.45% |
| 2022-03-31 | ₹10.36 Billion | ₹696.36 Million | 0.067x | -60.36% |
| 2021-03-31 | ₹9.13 Billion | ₹1.55 Billion | 0.170x | -55.88% |
| 2020-03-31 | ₹6.52 Billion | ₹2.51 Billion | 0.384x | +45.95% |
| 2019-03-31 | ₹5.43 Billion | ₹1.43 Billion | 0.263x | +71.88% |
| 2018-03-31 | ₹4.55 Billion | ₹697.66 Million | 0.153x | -63.96% |
| 2017-03-31 | ₹4.11 Billion | ₹1.75 Billion | 0.425x | +13.96% |
| 2016-03-31 | ₹3.57 Billion | ₹1.33 Billion | 0.373x | +9.88% |
| 2015-03-31 | ₹3.08 Billion | ₹1.05 Billion | 0.339x | -10.76% |
| 2014-03-31 | ₹2.51 Billion | ₹954.26 Million | 0.380x | +6.26% |
| 2013-03-31 | ₹2.08 Billion | ₹743.10 Million | 0.358x | +72.40% |
| 2012-03-31 | ₹1.76 Billion | ₹366.41 Million | 0.208x | +64.76% |
| 2011-03-31 | ₹1.63 Billion | ₹205.60 Million | 0.126x | -68.79% |
| 2010-03-31 | ₹1.46 Billion | ₹591.20 Million | 0.404x | -18.58% |
| 2009-03-31 | ₹1.23 Billion | ₹612.10 Million | 0.496x | +94.81% |
| 2008-03-31 | ₹1.12 Billion | ₹283.87 Million | 0.255x | -12.94% |
| 2007-03-31 | ₹1.00 Billion | ₹292.69 Million | 0.292x | -- |